immunosuppressants organ transplantation (immune system-mediated graft rejection) autoimmunity...
Post on 03-Jan-2016
222 Views
Preview:
TRANSCRIPT
immunosuppressants
Organ transplantation(immune system-mediated graft rejection)
Autoimmunity(immune system-mediated diseases)
Immunosuppressive drugs
Glucocorticoids
Calcineurin inhibitors
Antiproliferative/antimetabolic agents
Biologics (antibodies)
General Approach to Organ Transplantation Therapy Careful patient preparation and selection of
the best available ABO type-compatible HLA match for organ donation.
Combination therapy. Greater immunosuppression is required to
gain early engraftment and/or to treat established rejection, than to maintain long term immunosuppression.
Careful investigation of each episode of transplant dysfunction is required.
The drug should be reduced or withdrawn if its toxicity exceeds its benefit.
General approach to organ transplantation therapy
Biologic Induction Therapy
Maintenance Immunotherapy
Therapy for Established Rejection
Adrenocortical Steroids
Mechanism of Action: Steroids lyse and possibly induce redistribution
of lymphocytes, causing a rapid, transient decrease in peripheral blood lymphocyte count.
Steroids bind to receptors inside cells; either these receptors, glucocorticoid-induced proteins, or interacting proteins regulate the transcription of numerous other genes.
Adrenocortical Steroids
Mechanism of Action Glucocorticoid-receptor complexes increase
IkB expression, thereby curtailing activation of NF-kB1 which increases apoptosis of activated cells.
Downregulation of important proinflammatory cytokines, such as IL-1 and IL-6. T cells are inhibited from making IL-2 and proliferating.
Adrenocortical steroids
Mechanism of Action The activation of cytotoxic T lymphocytes is
inhibited. Neutrophil and monocytes display poor
chemotaxis and decreased lysosomal enzyme release.
Therefore, glucocorticoids have broad anti-inflammatory effects on cellular immunity.
In contrast, they have relatively little effect on humoral immunity.
Therapeutic Uses Glucocorticoids commonly are used in combination
with other immunosuppressive agents to both prevent and treat transplant rejection.
High doses of intravenous methylprednisolone sodium succinate (pulses) are used to reverse acute transplant rejection and acute exacerbations of selected autoimmune disorders.
Adrenocortical steroids
Therapeutic Uses They are efficacious for treatment of GVH
disease in BMT.
Glucocorticoids are used routinely to treat RA, SLE, systemic dermatomycositis, psoriasis, asthma, and other allergic disorders, IBD, inflammatory ophthalmic diseases, autoimmune hematologic disorders, and acute exacerbations of MS.
Adrenocortical steroids
ToxicityThe extensive use of steroids has resulted in
disabling and life-threatnening adverse effects in many patients. These effects include:
Growth retardation Avascular necrosis of bone Osteopenia
Increased risk of infection
Adrenocortical steroids
•Poor wound healing•Cataracts•Hyperglycemia•Hypertension
Calcineurin Inhibitors
Cyclosporine and Tacrolimus (FK506) After binding to cyclophilin or FKBP-12 block
the activity of calcineurine (a phospahtase).
Calcineurine-catalysed dephosphorylation is required for movement of a component of the nuclear factor of activated T lymphocytes (NFAT) into nucleus.
NFAT is required for induction of a number of cytokine genes, including that for IL-2 and T-cell GF and DF.
Cyclosporine
Is a cyclic polypeptide. Is lipophilic and highly hydrophobic. Can be administered intravenously or orally. Cyclosporine is extensively metabolized in the
liver by the cytochrom-P450 3A enzyme system. Cyclosporine and its metabolites are excreted
principally through the bile. In the presence of hepatic dysfunctions, dosage
adjustments are required.
Therapeutic Uses
Clinical indications for cyclosporine are kidney, liver, Heart and other organ transplantation; RA and psoriasis.
Cyclosporine usually is used in combination with other agents, especially glucocorticoids and either azathioprine or mycophenolate mophetile, most recently, sirolimus.
Cyclosporine
ToxicityThe principal adverse reactions to cyclosporine therapy are:Renal dysfunction HypertensionTremor HyperlipidemiaHirsutism Gum hyperplasiaCombined use of calcineurin inhibitors and glucocorticoids is particularly diabetogenic, with diabetes being more frequent in patients treated with FK than in those receiving cyclosporine.
Cyclosporine
Drug Interactions
Any drug that affects microsomal enzymes, especially the CYP3A system, may affect cyclosporine blood concenterations.
Cyclosporine
Inhibitors InducersCCBs NafcillinFluconazole, Ketokonazole RifampinErythromycine PhenobarbitalMethylprednisolone PhenytoinIndinavir OctreotideAllopurinol and metoclopramide
TiclopidinGrapefruit (Juice)
NSAIDs, MTX, Digoxin and Lovastatin
CyclosporineDrug Interactions
Tacrolimus (FK506)
Is a macrolid antibiotic. Is available for oral administration and
solution for injection. FK is extensively metabolized in liver by
CYP3A The bulk of excretion of parent drug and
metabolites in the feces. Less than 1% of administered drug is excreted unchanged in the urine.
Tacrolimus
Therapeutic Uses
Tacrolimus is indicated for the prophylaxis of solid-organ allograft
rejection in a manner similar to CsA and as rescue therapy in patients with
rejection episodes despite “ therapeutic” levels of CsA
Tacrolimus
Toxicity
Nephrotoxicity HyperkalemiaNeurotoxicity HyperglycemiaGI complaints DiabetesHypertension
As with other immunosuppressive agents, there is an increased risk of secondary tumors and apportunistic infections
Tacrolimus
Drug Interactions
The potential interactions described for cyclosporine apply for tacrolimus as well
Antiproliferative and Antimetabolic Drugs
Sirolimus (Rapamycin; RAPAMUNE) Is a macroyclic lactone Sirolimus inhibits T-lymphocyte activation
and proliferation downstream of the IL-2 and other T-cell growth factor receptors
The sirolimus-FKBP-12 complex binds to and inhibits the mammalian kinase (mTOR), which is a key enzyme in cell-cycle progression
Sirolimus
Therapeutic uses
Sirolimus is indicated for prophylaxis of organ transplant rejection in combination therapy with a calcineurin inhibitor and glucocorticoids.
Inhibition local cell proliferation
Toxicityo Increase in serum cholesterol and TGo Lympocoeleo Anemiao Leukopeniao Thrombocytopeniao Hypokalemia or hyperkalemiao Fever, Gastrointestinal effects
Sirolimus
Drug interactions
Dose adjustment may be required with coadministration of sirolimus with CsA, diltiazem or rifampin
Sirolimus
Azathioprine (IMURAN)
Mechanism of action
Following exposure to nucleaphiles (gluthathione), azathioprine is cleaved to 6-MP, which in turn, is converted to additional metabolites that inhibit de novo purine synthesis.
Azathioprine
Therapeutic Uses
It is indicated as an adjunct for prevention of organ transplant rejection and in sever RA.
Azathioprine
Toxicity
The major side effect of azathioprine is BMD, increased susceptibility to
infections, hepatotoxicity, alopecia, GI toxicity, pancreatitis and increased risk
of neoplasia
Azathioprine
Drug Interactions
Allopurinol
Adverse effects resulting from co- administration of azathioprine with other myelosuppressive agents or ACEIs include:
Leukopenia, thrembocytopenia and anemia as a result of myelosuppression
Mycophenolate Mofetile
Mechanism of action
Is a prodrug (MFA).
Is a selective, uncompetitive and reversible inhibitor of IMPDH, an important enzyme in the de novo pathway of guanine nucleotide synthesis.
Therapeutic Uses
Mycophenolate mofetile is indicated for prophylaxis of transplant rejection and is typically used in combination with glucocorticoids and a calcineurine inhibitor, but not with azathioprine
Mycophenolate Mofetile
Toxicity
The principal toxicities of mycophenolate mophetile are GI and hematologic. These include:
Leukopenia, diarrhea and vomiting. There also is an increased incidence of some infections, especially sepsis associated with cytomegalovirus
Mycophenolate Mofetile
Drug Interactions
Aluminium or magnesium hydroxide
Cholestyramine
Mycophenolate Mofetile
Other Antiproliferative and Cytotoxic Agents
MTX
Cyclophosphamide
Thalidomide
Chlorambucil
Leflunomide
top related